0HI3 Panoramica delle azioni Arrowhead Pharmaceuticals, Inc. sviluppa farmaci per il trattamento di malattie intrattabili negli Stati Uniti. Maggiori dettagli
Premi Analisi del rischio + 1 più rischio
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Arrowhead Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Arrowhead Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$19.60 Massimo di 52 settimane US$39.79 Minimo di 52 settimane US$17.24 Beta 0.93 Variazione di 1 mese 2.48% Variazione a 3 mesi 2.44% Variazione di 1 anno -36.59% Variazione a 3 anni -70.45% Variazione a 5 anni -69.65% Variazione dall'IPO 220.22%
Notizie e aggiornamenti recenti
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Dec 24
CEO, President & Director recently sold US$567k worth of stock Dec 22
Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases Dec 11
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity Dec 03
New minor risk - Revenue size Nov 27
Full year 2024 earnings released: US$4.82 loss per share (vs US$1.92 loss in FY 2023) Nov 27 Vedi altri aggiornamenti
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Dec 24
CEO, President & Director recently sold US$567k worth of stock Dec 22
Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases Dec 11
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity Dec 03
New minor risk - Revenue size Nov 27
Full year 2024 earnings released: US$4.82 loss per share (vs US$1.92 loss in FY 2023) Nov 27
Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors Nov 26 Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
New major risk - Financial position Sep 05
Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Sep 03
Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies Aug 15
New minor risk - Financial position Aug 09
Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023) Aug 09
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial Jun 26
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome Jun 05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma May 22
Now 22% undervalued after recent price drop May 11
Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023) May 10
Now 23% undervalued after recent price drop Apr 24
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease Apr 24
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo Apr 09
Chief Financial Officer recently sold US$1.4m worth of stock Mar 11
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy Mar 08
Now 27% overvalued after recent price rise Mar 01
First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023) Feb 07
Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024 Jan 27
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024 Jan 22
Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million. Jan 05
New major risk - Financial position Dec 06
New major risk - Financial position Nov 30
Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022) Nov 30
Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy Nov 29
Chief Medical Officer recently sold US$567k worth of stock Nov 23
Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 Nov 15
New minor risk - Share price stability Oct 05
New major risk - Revenue and earnings growth Sep 23
Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022) Aug 08
New minor risk - Insider selling Jul 03
Chief Financial Officer recently sold US$543k worth of stock Jul 02
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1 Jun 28
Chairman of the Board recently sold US$266k worth of stock May 10 May 03
Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022) May 03 Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022) Feb 07
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis Feb 03
Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023 Jan 31
Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics. Jan 22
Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Jan 10
Insufficient new directors Jan 01
Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study Dec 22
No longer forecast to breakeven Dec 01
Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline Nov 08
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3 Oct 12
Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021) Aug 05
Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer Jul 21
Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE Jul 06
Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine Jun 28
Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021) May 11
Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors May 03
Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia Apr 27
Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia Feb 25
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases Feb 19
Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 Feb 18
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 04
Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome Jan 13
Independent Director recently sold US$291k worth of stock Jan 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Nov 23
Chairman of the Board recently sold US$326k worth of stock Sep 14
Chief Commercial Officer James Hassard has left the company Sep 02
Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020) Aug 08
Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study Jul 03
Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia Jul 01
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress Jun 26
Chief Commercial Officer recently sold US$323k worth of stock Jun 25
Arrowhead Pharmaceuticals, Inc. Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH At EASL International Liver Congress Jun 24
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia Jun 04
Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.20 loss in 2Q 2020) May 06
Arrowhead Pharmaceuticals Inc. Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease Apr 29
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia Mar 03
Chairman of the Board recently sold US$100k worth of stock Feb 27
First quarter 2021 earnings released: US$0.20 loss per share (vs US$0.028 loss in 1Q 2020) Feb 06
Revenue misses expectations Feb 06
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia Jan 26
Chief Financial Officer recently sold US$1.1m worth of stock Jan 20
Chairman of the Board recently sold US$759k worth of stock Dec 22 Rendimenti per gli azionisti 0HI3 GB Biotechs GB Mercato 7D -9.6% -1.0% -0.6% 1Y -36.6% -24.1% 3.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 0HI3 ha avuto una performance inferiore rispetto al UK Biotechs che ha registrato un rendimento -24.1 % nell'ultimo anno.
Rendimento vs Mercato: 0HI3 ha avuto una performance inferiore al mercato UK che ha registrato un rendimento 3.1 % nell'ultimo anno.
Volatilità dei prezzi Is 0HI3's price volatile compared to industry and market? 0HI3 volatility 0HI3 Average Weekly Movement 10.4% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Prezzo delle azioni stabile: Il prezzo delle azioni di 0HI3 è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 10% ) di 0HI3 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni UK.
Informazioni sull'azienda Arrowhead Pharmaceuticals, Inc. sviluppa farmaci per il trattamento di malattie intrattabili negli Stati Uniti. La pipeline di prodotti dell'azienda comprende Plozasiran, che ha completato la sperimentazione clinica di Fase 3 per il trattamento dell'ipertrigliceridemia, della dislipidemia e della sindrome da chilomicronemia familiare; Olpasiran, che è in fase di sperimentazione clinica di Fase 3 per ridurre la produzione di apolipoproteina A; e Fazirsiran, che è in fase di sperimentazione clinica di Fase 3 per il trattamento della malattia epatica associata alla carenza di alfa-1 antitripsina. L'azienda sviluppa anche Zodasiran, in fase 2b di sperimentazione clinica per il trattamento della dislipidemia e dell'ipertrigliceridemia, GSK-4532990 per il trattamento della steatoepatite associata a disfunzione metabolica (MASH) e Daplusiran/Tomligisiran, in fase 2 di sperimentazione clinica per il trattamento dell'epatite B cronica.
Mostra di più Arrowhead Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Arrowhead Pharmaceuticals con la sua capitalizzazione di mercato? 0HI3 statistiche fondamentali Capitalizzazione di mercato US$2.44b Guadagni(TTM ) -US$599.49m Ricavi(TTM ) US$3.55m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 0HI3 Conto economico (TTM ) Ricavi US$3.55m Costo del fatturato US$0 Profitto lordo US$3.55m Altre spese US$603.04m Guadagni -US$599.49m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -4.82 Margine lordo 100.00% Margine di profitto netto -16,882.37% Rapporto debito/patrimonio netto 384.5%
Come si è comportato 0HI3 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/25 13:42 Prezzo dell'azione a fine giornata 2024/12/24 00:00 Guadagni 2024/09/30 Guadagni annuali 2024/09/30
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Arrowhead Pharmaceuticals, Inc. è coperta da 29 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Ishan Majumdar Baptista Research Ying Huang Barclays Jason Matthew Gerberry BofA Global Research
Mostra 26 altri analisti 